T. Rowe Price Associates’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $473K | Buy |
58,094
+12,367
| +27% | +$106K | ﹤0.01% | 2485 |
|
|
2025
Q4 | $476K | Buy |
45,727
+3,768
| +9% | +$39.5K | ﹤0.01% | 2419 |
|
|
2025
Q3 | $372K | Buy |
41,959
+2,386
| +6% | +$17K | ﹤0.01% | 2501 |
|
|
2025
Q2 | $229K | Buy |
39,573
+7,855
| +25% | +$48.1K | ﹤0.01% | 2657 |
|
|
2025
Q1 | $210K | Buy |
31,718
+3,648
| +13% | +$28.4K | ﹤0.01% | 2611 |
|
|
2024
Q4 | $245K | Buy |
28,070
+4,344
| +18% | +$62.5K | ﹤0.01% | 2603 |
|
|
2024
Q3 | $464K | Buy |
23,726
+672
| +3% | +$13.6K | ﹤0.01% | 2280 |
|
|
2024
Q2 | $475K | Buy |
23,054
+2,906
| +14% | +$59.7K | ﹤0.01% | 2207 |
|
|
2024
Q1 | $430K | Buy |
20,148
+2,940
| +17% | +$57.2K | ﹤0.01% | 2271 |
|
|
2023
Q4 | $248K | Sell |
17,208
-17,659
| -51% | -$174K | ﹤0.01% | 2455 |
|
|
2023
Q3 | $318K | Buy |
34,867
+10,499
| +43% | +$107K | ﹤0.01% | 2310 |
|
|
2023
Q2 | $258K | Buy |
24,368
+608
| +3% | +$7.19K | ﹤0.01% | 2435 |
|
|
2023
Q1 | $291K | Buy |
23,760
+975
| +4% | +$12.2K | ﹤0.01% | 2356 |
|
|
2022
Q4 | $283K | Sell |
22,785
-3,963
| -15% | -$57.6K | ﹤0.01% | 2395 |
|
|
2022
Q3 | $366K | Sell |
26,748
-11,048
| -29% | -$170K | ﹤0.01% | 2284 |
|
|
2022
Q2 | $693K | Buy |
37,796
+423
| +1% | +$6.08K | ﹤0.01% | 2068 |
|
|
2022
Q1 | $601K | Buy |
37,373
+15,296
| +69% | +$221K | ﹤0.01% | 2258 |
|
|
2021
Q4 | $309K | Sell |
22,077
-17,278
| -44% | -$280K | ﹤0.01% | 2588 |
|
|
2021
Q3 | $737K | Buy |
39,355
+6,336
| +19% | +$119K | ﹤0.01% | 2195 |
|
|
2021
Q2 | $688K | Buy |
33,019
+1,273
| +4% | +$31.6K | ﹤0.01% | 2233 |
|
|
2021
Q1 | $897K | Buy |
31,746
+7,924
| +33% | +$251K | ﹤0.01% | 2110 |
|
|
2020
Q4 | $778K | Buy |
23,822
+2,926
| +14% | +$103K | ﹤0.01% | 2048 |
|
|
2020
Q3 | $640K | Buy |
+20,896
| New | +$461K | ﹤0.01% | 1990 |
|
Other funds holding KURA
SCM
BI
VCM
AC
PM
DTC
